Moreover, in HER2-positive breast cancer patients, EV-associated TGF-β1 levels correlate with response to HER2-targeted therapy, proposing TGF-β1 as an EV-associated biomarker to monitor the treatment response [83]. Here, ERBB2 is linked to breast cancer.